Lung-resident mesenchymal stromal cells. A new player in post-transplant bronchiolitis obliterans syndrome?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. An overview on small molecule-induced differentiation of mesenchymal stem cells into beta cells for diabetic therapy.Stem cell research & therapy · 2019
   Review
2. Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options.Clinical and translational medicine · 2019
   Review
3. Platelet-derived SDF-1 primes the pulmonary capillary vascular niche to drive lung alveolar regeneration.Nature cell biology · 2015
   Article
4. Role of stem/progenitor cells in reparative disorders.Fibrogenesis & tissue repair · 2012
   Article

Corrections and comments

• Comment on
  Mesenchymal stromal cells in bronchoalveolar lavage as predictors of bronchiolitis obliterans syndrome.2011

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as